New hope for kids with relapsed leukemia: donor immune cells enter trial
NCT ID NCT06080191
First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 27 times
Summary
This early-stage trial tests a new treatment for children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. Doctors take immune cells from a healthy donor, modify them to recognize and attack leukemia cells, and give them to the patient. The main goals are to find a safe dose and check for side effects, including graft-versus-host disease. Up to 24 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Italy, 00165, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.